Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 1/2012

01-03-2012 | Pharmacologic Therapy (W. H. Wilson Tang, Section Editor)

Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges

Authors: Jasmine A. Talameh, David E. Lanfear

Published in: Current Heart Failure Reports | Issue 1/2012

Login to get access

Abstract

The individual patient responses to chronic heart failure (HF) pharmacotherapies are highly variable. This variability cannot be entirely explained by clinical characteristics, and genetic variation may play a role. Therefore, this review will summarize the background pharmacogenetic literature for major HF pharmacotherapy classes (ie, β-blockers, angiotensin-converting enzyme inhibitors, digoxin, and loop diuretics), evaluate recent advances in the HF pharmacogenetic literature in the context of previous findings, and discuss the challenges and conclusions for HF pharmacogenetic data and its clinical application.
Literature
1.
MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82(1):57–61.PubMed
2.
Chen L, Meyers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics. 2007;17(11):941–9.PubMedCrossRef
3.
Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14(5):388–93.PubMedCrossRef
4.
Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871–8.PubMedCrossRef
5.
MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.CrossRef
6.
The SOLVD. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991;325(5):293–302.CrossRef
7.
Lanfear DE, McLeod HL. Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician. 2007;76(8):1179–82.PubMed
8.
Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–53.PubMedCrossRef
9.
Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274(18):12670–4.PubMedCrossRef
10.
Mialet-Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9(10):1300–5.PubMedCrossRef
11.
Terra SG, Hamilton KK, Pauly DF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005;15(4):227–34.PubMedCrossRef
12.
Luo M, Bi Y, Xu YX. Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure. Chin Med J (Engl). 2007;120(19):1720–3.
13.
Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103(30):11288–93.PubMedCrossRef
14.
Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–67.CrossRef
15.
Bristow MR, Krause-Steinrauf H, Nuzzo R, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004;110(11):1437–42.PubMedCrossRef
16.
Biolo A, Clausell N, Santos KG, et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol. 2008;102(6):726–32.PubMedCrossRef
17.
• Sehnert AJ, Daniels SE, Elashoff M, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008;52(8):644–651. This was a large observational cohort that found in mostly treated HF patients, there was no association of common variants in adrenergic receptors with survival. PubMedCrossRef
18.
White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003;5(4):463–8.PubMedCrossRef
19.
Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59(3):297–309.PubMed
20.
Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33(32):9414–9.PubMedCrossRef
21.
Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 1995;13(1):25–33.PubMed
22.
Kaye DM, Smirk B, Williams C, et al. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003;13(7):379–82.PubMedCrossRef
23.
Troncoso R, Moraga F, Chiong M, et al. Gln(27)– > Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Pharmacol Toxicol. 2009;104(5):374–8.PubMedCrossRef
24.
Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther. 2010;24(1):49–60.PubMedCrossRef
25.
de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics. 2005;15(3):137–42.PubMedCrossRef
26.
Nonen S, Okamoto H, Fujio Y, et al. Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J. 2008;8(1):78–84.PubMedCrossRef
27.
Shin J, Lobmeyer MT, Gong Y, et al. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol. 2007;99(2):250–5.PubMedCrossRef
28.
Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102(8):1534–9.PubMedCrossRef
29.
Neumeister A, Charney DS, Belfer I, et al. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics. 2005;15(3):143–9.PubMedCrossRef
30.
•• Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3(1):21–28. This was a large (n = 1040) pharmacogenetic substudy of the BEST trial. They found bucindolol lowered cardiovascular mortality in ADRA2C-insertion homozygotes but not deletion carriers. PubMedCrossRef
31.
Lobmeyer MT, Gong Y, Terra SG, et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics. 2007;17(4):277–82.PubMedCrossRef
32.
Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol. 2003;63(1):9–18.PubMedCrossRef
33.
•• Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14(5):510–517. This paper consisted of in vitro, case–control, and prospective observational studies. The authors found no difference in transplant-free survival in GRK5 Leu41-carriers regardless of BB treatment status. Also, BB-naïve Leu41-carriers had longer transplant-free survival than BB-naïve Gln41 homozygotes. PubMedCrossRef
34.
•• Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long–term survival in heart failure. J Am Coll Cardiol. 2009;54(5):432–444. This was a large (n = 2460) pharmacogenetic study of ADRB1, Arg389Gly, and GRK5 Gln41Leu. The authors found that these genetic variants, rather than race, are the major contributors to the difference in BB treatment effect in African-Americans and Caucasians. PubMedCrossRef
35.
• Baudhuin LM, Miller WL, Train L, et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol. 2010;106(3):402–408. This recent study found that common variants in ADRB1, CYP2D6, and UGT1A1 were not associated with a clinical response to metoprolol or carvedilol therapy, but variants in ADRB1 and CYP2D6, alone and in haplotype, were significantly associated with the dose of carvedilol. PubMedCrossRef
36.
• Petersen M, Andersen JT, Hjelvang BR, et al. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol. 2011;71(4):556–565. This recent study demonstrates that there may be differential pharmacogenetic interaction depending on specific BB, as there was a significant interaction with carvedilol and not metoprolol. PubMedCrossRef
37.
Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343–6.PubMedCrossRef
38.
O’Toole L, Stewart M, Padfield P, et al. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol. 1998;32(6):988–94.PubMedCrossRef
39.
Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol. 2001;37(7):1808–12.PubMedCrossRef
40.
Tang WH, Vagelos RH, Yee YG, et al. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. Am Heart J. 2004;148(5):889–94.PubMedCrossRef
41.
McNamara DM, Holubkov R, Postava L, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44(10):2019–26.PubMedCrossRef
42.
Tiago AD, Badenhorst D, Skudicky D, et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res. 2002;54(3):584–9.PubMedCrossRef
43.
Cuoco MA, Pereira AC, Mota Gde F, et al. Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure. Arq Bras Cardiol. 2008;90(4):252–6.PubMedCrossRef
44.
• Wu CK, Luo JL, Tsai CT, et al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J. 2010;10(1):46–53. This paper extends the pharmacogenetic interaction between the ACE insertion/deletion and ACE inhibitors to HF patients with preserved LVEF. PubMedCrossRef
45.
Vormfelde SV, Engelhardt S, Zirk A, et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther. 2004;76(6):557–66.PubMedCrossRef
46.
Vormfelde SV, Schirmer M, Hagos Y, et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol. 2006;62(3):323–35.PubMedCrossRef
47.
Vormfelde SV, Toliat MR, Schirmer M, et al. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;83(6):815–7.PubMedCrossRef
48.
Vormfelde SV, Sehrt D, Toliat MR, et al. Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007;82(3):300–9.PubMedCrossRef
49.
Werner D, Werner U, Meybaum A, et al. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet. 2008;47(5):323–32.PubMedCrossRef
50.
• Vormfelde SV, Brockmoller J. The genetics of loop diuretic effects. Pharmacogenomics J. 2010; [Epub ahead of print]. This paper demonstrates that genetic variation seems to be a stronger predictor of the loop diuretic drug response than pharmacokinetic variation.
51.
Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):e1–e194.CrossRef
52.
Birkenfeld AL, Jordan J, Hofmann U, et al. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin Pharmacol Ther. 2009;86(6):605–8.PubMedCrossRef
53.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473–8.PubMedCrossRef
54.
Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002;72(5):584–94.PubMedCrossRef
55.
Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72(2):209–19.PubMedCrossRef
56.
Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003;58(12):809–12.PubMed
57.
Comets E, Verstuyft C, Lavielle M, et al. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur J Clin Pharmacol. 2007;63(5):437–49.PubMedCrossRef
58.
Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest. 2007;67(2):123–34.PubMedCrossRef
59.
Xu P, Jiang ZP, Zhang BK, et al. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology. 2008;82(3):221–7.PubMedCrossRef
60.
• Aarnoudse AJ, Dieleman JP, Visser LE, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008;18(4):299–305. This paper extended the digoxin pharmacogenetic findings from single-dose healthy volunteer studies to a population of steady-state digoxin-using patients. They found that the common ABCB1 C1236T, G2677T, and C3435T variants and the associated TTT haplotype were associated with higher SDC. PubMedCrossRef
61.
Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol. 2002;54(6):610–6.PubMedCrossRef
62.
Chowbay B, Li H, David M, et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol. 2005;60(2):159–71.PubMedCrossRef
63.
Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res. 2002;19(10):1581–5.PubMedCrossRef
64.
Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18(10):1400–4.PubMedCrossRef
65.
• Neuvonen AM, Palo JU, Sajantila A. Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users. Int J Legal Med. 2011;125(2):265–269. This recent paper demonstrates that the pharmacogenetic interaction between ABCB1 C3435T and digoxin may be sex-specific. PubMedCrossRef
66.
Adams Jr KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497–504.PubMedCrossRef
67.
McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001;103(12):1644–8.PubMed
68.
Borjesson M, Magnusson Y, Hjalmarson A, et al. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J. 2000;21(22):1853–8.PubMedCrossRef
69.
Terra SG, Pauly DF, Lee CR, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005;77(3):127–37.PubMedCrossRef
70.
Magnusson Y, Levin MC, Eggertsen R, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005;78(3):221–31.PubMedCrossRef
71.
Muthumala A, Drenos F, Elliott PM, et al. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail. 2008;10(1):3–13.PubMedCrossRef
72.
Littlejohn MD, Palmer BR, Richards AM, et al. Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment. Eur J Heart Fail. 2008;10(1):55–9.PubMedCrossRef
73.
Taylor MR, Slavov D, Humphrey K, et al. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics. 2009;19(1):35–43.PubMedCrossRef
74.
Cicoira M, Rossi A, Bonapace S, et al. Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am J Med. 2004;116(10):657–61.PubMedCrossRef
75.
de Denus S, Zakrzewski-Jakubiak M, Dube MP, et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother. 2008;42(7):925–32.PubMedCrossRef
76.
McNamara DM, Tam SW, Sabolinski ML, et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol. 2006;48(6):1277–82.PubMedCrossRef
77.
McNamara DM, Tam SW, Sabolinski ML, et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail. 2009;15(3):191–8.PubMedCrossRef
Metadata
Title
Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges
Authors
Jasmine A. Talameh
David E. Lanfear
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 1/2012
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-011-0076-2

Other articles of this Issue 1/2012

Current Heart Failure Reports 1/2012 Go to the issue

Pharmacologic Therapy (W. H. Wilson Tang, Section editor)

Medical Therapy for Acute Decompensated Heart Failure: What Recent Clinical Trials Have Taught Us About Diuretics and Vasodilators

Pharmacologic Therapy (WHW Tang, Section Editor)

Should We Start Prescribing Omega-3 Polyunsaturated Fatty Acids in Chronic Heart Failure?

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

Surgical Approach to Mitral Regurgitation in Chronic Heart Failure: When Is It an Option?

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK HASAN, Section Editor)

Resistance Versus Aerobic Exercise Training in Chronic Heart Failure

Pharmacologic Therapy (W. H. Wilson Tang, Section Editor)

Pharmacologic Strategies to Target Oxidative Stress in Heart Failure

Pharmacologic Therapy (W. H. Wilson Tang, Section editor)

Cardiac Gene Therapy: From Concept to Reality
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits